Integration of Different “-omics” Technologies Identifies Inhibition of the IGF1R-Akt-mTOR Signaling Cascade Involved in the Cytotoxic Effect of Shikonin against Leukemia Cells

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment

(2015) Alberto M. Martelli et al.   Oncotarget

A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse

(2013) S Park et al.   LEUKEMIA

UniQua: A Universal Signal Processor for MS-Based Qualitative and Quantitative Proteomics Applications

(2012) Wei-Hung Chang et al.   ANALYTICAL CHEMISTRY

Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention

(2012) W. J. Norde et al.   BLOOD

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Shikonin Directly Targets Mitochondria and Causes Mitochondrial Dysfunction in Cancer Cells

(2012) Benjamin Wiench et al.   Evidence-based Complementary and Alternative Medicine

Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies

(2012) Alberto M Martelli et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The translational landscape of mTOR signalling steers cancer initiation and metastasis

(2012) Andrew C. Hsieh et al.   NATURE

Lenalidomide for Multiple Myeloma

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107)

(2011) Sergio Amadori et al.   BRITISH JOURNAL OF HAEMATOLOGY

Visual Indicator for Surfactant Abundance in MS-Based Membrane and General Proteomics Applications

(2010) Chao-Jung Chen et al.   ANALYTICAL CHEMISTRY

Curcumin Stimulates Reactive Oxygen Species Production and Potentiates Apoptosis Induction by the Antitumor Drugs Arsenic Trioxide and Lonidamine in Human Myeloid Leukemia Cell Lines

(2010) Y. Sanchez et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

(2010) N Chapuis et al.   LEUKEMIA

mTORC1 signalling and mRNA translation: Figure 1

(2009) Christopher G. Proud   BIOCHEMICAL SOCIETY TRANSACTIONS

Targeting the mTOR Signaling Network for Cancer Therapy

(2009) Funda Meric-Bernstam et al.   JOURNAL OF CLINICAL ONCOLOGY

AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

(2009) Oleg Trott et al.   JOURNAL OF COMPUTATIONAL CHEMISTRY

Target profiling of small molecules by chemical proteomics

(2009) Uwe Rix et al.   Nature Chemical Biology

Integrated Genomic and Pharmacological Approaches to Identify Synthetic Lethal Genes as Cancer Therapeutic Targets

(2008) Shinji Mizuarai et al.   CURRENT MOLECULAR MEDICINE